BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

892 related articles for article (PubMed ID: 12715124)

  • 1. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
    Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
    Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests.
    Friedrich MG; Hellstern A; Hautmann SH; Graefen M; Conrad S; Huland E; Huland H
    J Urol; 2002 Aug; 168(2):470-4. PubMed ID: 12131290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence?
    Friedrich MG; Hellstern A; Toma MI; Hammerer P; Huland H
    Eur Urol; 2003 Feb; 43(2):146-50; discussion 150-1. PubMed ID: 12565772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
    Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
    BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
    Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
    Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
    Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.
    Lekili M; Sener E; Demir MA; Temeltaş G; Müezzinoğlu T; Büyüksu C
    Urol Res; 2004 May; 32(2):124-8. PubMed ID: 14685796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.
    Toma MI; Friedrich MG; Hautmann SH; Jäkel KT; Erbersdobler A; Hellstern A; Huland H
    World J Urol; 2004 Jun; 22(2):145-9. PubMed ID: 14991320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.
    Coskuner E; Cevik I; Ozkan A; Dillioglugil O; Akdas A
    Int Urol Nephrol; 2012 Jun; 44(3):793-8. PubMed ID: 22371126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumor markers for bladder cancer: up-to-date study by the Kiel Tumor Bank].
    Hautmann S; Eggers J; Meyhoff H; Melchior D; Munk A; Hamann M; Naumann M; Braun PM; Jünemann KP
    Urologe A; 2007 Nov; 46(11):1508-13. PubMed ID: 17932643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
    Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
    Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma.
    Mansoor I; Calam RR; Al-Khafaji B
    Anal Quant Cytol Histol; 2008 Feb; 30(1):25-32. PubMed ID: 18459584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?
    Wiener HG; Mian C; Haitel A; Pycha A; Schatzl G; Marberger M
    J Urol; 1998 Jun; 159(6):1876-80. PubMed ID: 9598479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine.
    Golijanin D; Sherman Y; Shapiro A; Pode D
    Urology; 1995 Aug; 46(2):173-7. PubMed ID: 7624989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Urine cytology and urine markers. Significance for clinical practice].
    Tritschler S; Zaak D; Knuechel R; Stief CG
    Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.